As per the letter atatched

10th August, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, G. Block, Bandra Kurla Dalal Street, Complex, Bandra (East), Mumbai 400 001 Mumbai - 400 051 Script Code: 500259 Script Code: LYKALABS Sub: Submission of Press Release on Unaudited Financial Results for the First Quarter ended June 30, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release being issued by the Company today, regarding the Unaudited Financial Results of the Company for the first quarter ended June 30, 2026. The Board of Directors at its meeting held today, i.e., August 10, 2026, has inter-alia approved the said financial results. The above information will also be made available on the website of the Company at www.lykalabs.com We request you to kindly take the same on your record. Thanking you, Yours faithfully, For Lyka Labs Limited Shailendra Agrawal Company Secretary and Compliance Officer Encl.: as above Press Release Lyka Labs Limited Q1 FY27 Unaudited Financials Results Mumbai, August 10, 2026 : Lyka Labs Limited today announced its unaudited financial results for the first quarter ended 30th June 2026 of the financial year 2026-27 Key Financials of Q1 FY27 ◦ Stanalone Net Total Income up 42.67% at Rs. 4272.79 Lacs. ◦ Consolidated Net Total Income up 26.95% at Rs. 4272.79 Lacs. ◦ Domestic Revenue up 15.91% at Rs. 2652.11 Lacs. ◦ Export Revenue up 68.03 % at Rs. 1483.42 Lacs. ◦ Standalone EBITDA margin @ 11.84% in Q1 FY27 as against 14.16% in Q1 FY26 ◦ Consolidated EBITDA margin @ 11.74% in Q1 FY27 as against 13.07% in Q1 FY26 ◦ Standalone Net Profit up 159.04 % at Rs. 210.01 Lacs. ◦ Consolidated Net Profit up 105.44 % at Rs. 204.66 Lacs. Standalone Q1 FY27 at a glance (Rs. In lacs) Particulars Q1 FY27 Q1 FY26 Growth in % Revenue from Operations 4230.94 2917.64 4 5.01 EBITDA 501.12 413.06 2 1.32 Other Income 41.85 7 7.34 -45.89 Finance Cost 100.82 8 5.14 1 8.42 Depreciation and amortisation 200.96 211.18 -4.84 Net Profit after tax 199.33 116.74 7 0.75 Consolidated Q1 FY27 at a glance (Rs. In lacs) Particulars Q1 FY27 Q1 FY26 Growth in % Revenue from Operations 4230.94 3302.54 2 8.11 EBITDA 496.57 431.73 1 5.02 Other Income 41.85 6 3.09 -33.67 Finance Cost 100.81 8 5.38 1 8.07 Depreciation and amortisation 200.96 211.18 -4.84 Net Profit after tax 194.80 135.17 4 4.11 Q1 FY27 Revenue Break-up (Rs. In lacs) Particulars Q1 FY27 Q1 FY26 Growth in % Domestic Branded Formulation 737.67 454.58 6 2.27 Branded Veterinary 587.35 296.90 9 7.83 P2P 1,327.09 1,536.69 -13.64 Total Domestic Sales 2,652.11 2,288.17 1 5.91 Exports Branded Formulation 1,483.42 882.85 6 8.03 Total Export Sales 1,483.42 882.85 Other Operating Income 9 5.41 131.52 -27.46 Consolidated Revenue from Operations 4,230.94 3,302.54 Other Income 41.85 63.09 -33.67 Consolidated Net Total Income 4,272.79 3,365.63 26.95 About Lyka Labs Limited: Lyka Labs Limited is in the field of Manufacturing & Marketing of Finished Formulations for Human & Animal Healthcare, across various therapeutic segments. Shailendra Kumar Agarwal Company Secretary